RE: Covid bull run over?20 Jan 2022 13:46
This was a very small trial and had complications which i will not go into here. Folks can read the detail in many published articles, if they so wish. Mene Pangolos decided it was not worth pursuing, and a few other drugs at the time, which have since proven to be successful.
In 2016 after AZ dropped the Phase 2a study Professor Stephen Holgate said:
“New treatments to prevent severe exacerbations are needed and most exacerbations are caused by the common cold and flu. Unexpectedly, colds did not cause as many asthma exacerbations as were predicted in this clinical trial population. We hope to learn from the results of this trial which population within severe asthma, or other respiratory diseases, will most benefit from AZD9412 and should be included in future trials.”
Synairgen have learnt lessons. Delta spread through Western world..........Omicicron is spreading through the western world...........
Endpoints have been carefully choreographed for SG018 in breathless patients, more specific than in the P2. I believe the signs a strikingly optimistic, notwithstanding, all we have learned from the P2 and dissected to death (see Lancet)
They know the results already for P3 and have already advertised for numerous positions in the USA and strengthened staff substantially and set up many agreements ready for potential launch.
Tick tock
GLA.
Hoooooooooooooooooooooolllllllllllllllllllllllllllllllllldddddddddddddddddddddddddddd.